搜索
HCW Biologics Inc
HCWB添加自选
1.120USD
+0.783+232.31%
交易中 （美东）报价延迟15分钟
2.94M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+232.31%
5天
+249.64%
1月
+223.67%
6月
-62.67%
今年开始到现在
+15.38%
1年
-87.29%
TradingKey HCW Biologics Inc股票评分
单位: USD 更新时间: 2026-05-14操作建议
HCW Biologics Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名187/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价2.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
HCW Biologics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
HCW Biologics Inc亮点
亮点风险
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
业绩增长期
公司处于发展阶段，最新年度总收入54.23K美元
估值高估
公司最新PE估值-0.03，处于3年历史高位
机构加仓
最新机构持股465.64K股，环比增加39.47%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.60
分析师目标
根据
1
位分析师
买入
评级
2.000
目标均价
+472.41%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
HCW Biologics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
HCW Biologics Inc简介
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
公司代码HCWB
公司HCW Biologics Inc
CEOWong (Hing C)
网址https://hcwbiologics.com/
相关品种
